Designed to treat prostate cancer and preserve function.
ImmunoPDT is a clinical-stage, function-preserving photodynamic therapy for early prostate cancer, designed to treat the cancer while aiming to preserve continence and sexual function.
Active surveillance treats nothing. Radical treatment risks lasting harm. ImmunoPDT is designed to close that gap, treating the cancer while aiming to preserve function.
Sublingual Immuno1, activated by targeted red light.
Sublingual administration
The patient receives Immuno1, a sublingual photosensitising agent.
Localises in target tissue
Immuno1 is formulated to be taken up preferentially by prostate tissue, a key design improvement over earlier photodynamic therapies.
Targeted light activation
Once the agent is taken up, a red-light diffuser placed in the prostate activates it (660 nm), which is designed to destroy the tumour locally and to prompt a local immune response, the "Immuno" in ImmunoPDT.
Ten years of human follow-up, and a Phase 2 programme in Australia.
ImmunoPDT at the AUA Innovation Nexus Forum: clinician interest and a new Principal Investigator
NIIM completes recruitment for the Prostate Cancer PDT Study
Published: metronomic photodynamic therapy for local prostate cancer
Published case series: sublingual chlorophyll-based photodynamic therapy
A photodynamic therapy with potential across a range of solid tumours, starting with prostate, the most clinically and commercially significant.
Request information